Search clinical trials for: recomon (Epoetin Beta)

Total 6474 results

Hoffmann-La Roche

Completed

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Anemia

Russian Federation
JW Pharmaceutical

Completed

Study of Erythropoietin (EPO) Administration Schedule

Chronic Renal Failure | Anaemia

Korea, Republic of
University of Zurich

Unknown

Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans

Healthy

Switzerland
Hoffmann-La Roche

Completed

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Thailand
Hoffmann-La Roche

Terminated

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Anemia

Venezuela
Hoffmann-La Roche

Terminated

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Anemia

Venezuela
Thammasat University

Unknown

Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery

Acute Renal Failure

Thailand
Hamad Medical Corporation

Completed

Comparison Among Erythropoietin Stimulating Agents

Anemia of End Stage Renal Disease

Qatar
Western Galilee Hospital-Nahariya

Unknown

Prevention of Contrast Induced Nephropathy by Erythropoietin

Diabetes | Chronic Kidney Insufficiency

Israel
Seoul National University Bundang Hospital

Completed

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery (EPO-CABG)

Kidney Failure, Acute

Korea, Republic of
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Huiqing Sun
Göteborg University; Zhengzhou University

Enrolling by invitation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (EPO)

Developmental Disabilities
Zhengzhou University
Göteborg University; Zhengzhou Children's Hospital, China

Completed

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Premature Infants

China
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
China Medical University Hospital

Unknown

Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants

Retinopathy of Prematurity | Intraventricular Hemorrhage | Infant, Premature | Leukomalacia, Periventricular

Taiwan
InCROM Europe Clinical Research

Completed

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

Anaemia | Chronic Kidney Failure
Hoffmann-La Roche

Completed

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

China, Hong Kong
Hoffmann-La Roche

Completed

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Anemia

China
Leiden University Medical Center

Completed

PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Patients Receiving a Kidney From a Non-Heart-Beating Donor

Netherlands
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy

Anemia

Hungary
Hoffmann-La Roche

Completed

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Anemia

Italy, Spain, Sweden, Hong Kong, Greece, Ireland, United Kingdom, Portugal, Taiwan, Turkey, France, Germany, Russian Federation, Belgium, Austria, Thailand, Poland, Czech Republic, Denmark, Finland, Norway, Mexico
Hoffmann-La Roche

Completed

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Anemia, Neoplasms

France
Chugai Pharmaceutical

Completed

Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients

Anemia

Japan
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Predialysis Patients

Japan
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

Anemia

Bulgaria
Charite University, Berlin, Germany
University Hospital, Strasbourg, France; University of Zurich; Hoffmann-La Roche and other collaborators

Completed

Erythropoietin Treatment in Extremely Low Birth Weight Infants (EPO)

Anemia | Infant, Low Birth Weight

Germany
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Germany, Italy, United States, Taiwan, Canada, Puerto Rico, Spain, Thailand, Portugal, United Kingdom, Poland
Groupe Francophone des Myelodysplasies

Completed

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (EPO-QoL)

Myelodysplastic Syndromes

France
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Anemia

Morocco
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia

Anemia

Bulgaria
University Hospital, Grenoble
Roche Pharma AG

Completed

Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB (EPOetCEC)

Myocardial Ischemia

France
University of Cambridge
Hoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)

Completed

Erythropoietin Therapy for Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage

United Kingdom
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Anemia, Kidney Transplantation

Germany
Hoffmann-La Roche

Completed

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

Anemia

France
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Anemia

United States, Canada, United Kingdom, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Anemia

Egypt
Hoffmann-La Roche

Completed

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Kidney Disease, Chronic

Slovenia
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients

Anemia in Pre-Dialysis Patients

Japan
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Anemia

Belgium
Hoffmann-La Roche

Completed

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Anemia

Italy, Spain, United States, Germany
Hoffmann-La Roche

Completed

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Anemia

India
Hoffmann-La Roche

Completed

Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

Renal Impairment | Renal Anemia of Chronic Kidney Disease

Germany
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis (IMPACT)

Chronic Kidney Diseases

Israel
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Bayer

Completed

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE4)

Renal Insufficiency, Chronic | Anemia

United States, Japan
First Affiliated Hospital Xi'an Jiaotong University
Xijing Hospital; Shaanxi Provincial People's Hospital; Second Affiliated Hospital... and other collaborators

Unknown

Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome

Cerebral Palsy | Intracranial Hemorrhages | Premature Infants | Periventricular Leukomalacia

China

3

Subscribe